1513879-19-0 Usage
Uses
Used in Antimalarial Applications:
KDU691 is used as an antimalarial agent for the treatment of malaria caused by Plasmodium species. It exhibits potent inhibition of P. vivax PI4K, leading to the disruption of essential cellular processes in the parasite. KDU691 is effective against P. falciparum and P. yoelii schizonts, as well as P. cynomolgi schizonts and hypnozoites, demonstrating its potential in treating various forms of malaria.
Used in Pharmaceutical Research:
KDU691 is used as a research tool in the development of novel antimalarial drugs. Its selective inhibition of P. vivax PI4K makes it a valuable compound for studying the underlying mechanisms of malaria parasite survival and for identifying potential targets for new therapeutic interventions.
Used in Drug Development:
KDU691 serves as a lead compound in the development of new drugs targeting PI4K for the treatment of malaria. Its high potency and selectivity for P. vivax PI4K make it an attractive starting point for the design and optimization of more effective and safer antimalarial agents.
Used in Preclinical Studies:
KDU691 is used in preclinical studies to evaluate its safety, efficacy, and pharmacokinetic properties in animal models of malaria. These studies provide valuable information on the potential of KDU691 as a therapeutic agent and help guide the design of future clinical trials.
Used in Drug Resistance Research:
KDU691 is used to investigate the mechanisms of drug resistance in Plasmodium species. Its potent and selective inhibition of PI4K can help researchers understand how parasites develop resistance to antimalarial drugs and inform the development of strategies to overcome resistance.
Check Digit Verification of cas no
The CAS Registry Mumber 1513879-19-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,1,3,8,7 and 9 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1513879-19:
(9*1)+(8*5)+(7*1)+(6*3)+(5*8)+(4*7)+(3*9)+(2*1)+(1*9)=180
180 % 10 = 0
So 1513879-19-0 is a valid CAS Registry Number.
1513879-19-0Relevant articles and documents
Lead optimization of imidazopyrazines: A new class of antimalarial with activity on Plasmodium liver stages
Zou, Bin,Nagle, Advait,Chatterjee, Arnab K.,Leong, Seh Yong,Tan, Liying Jocelyn,Sim, Wei Lin Sandra,Mishra, Pranab,Guntapalli, Prasuna,Tully, David C.,Lakshminarayana, Suresh B.,Lim, Chek Shik,Tan, Yong Cheng,Abas, Siti Nurdiana,Bodenreider, Christophe,Kuhen, Kelli L.,Gagaring, Kerstin,Borboa, Rachel,Chang, Jonathan,Li, Chun,Hollenbeck, Thomas,Tuntland, Tove,Zeeman, Anne-Marie,Kocken, Clemens H. M.,McNamara, Case,Kato, Nobutaka,Winzeler, Elizabeth A.,Yeung, Bryan K. S.,Diagana, Thierry T.,Smith, Paul W.,Roland, Jason
, p. 947 - 950 (2014/10/15)
Imidazopyridine 1 was identified from a phenotypic screen against P. falciparum (Pf) blood stages and subsequently optimized for activity on liver-stage schizonts of the rodent parasite P. yoelii (Py) as well as hypnozoites of the simian parasite P. cynomolgi (Pc). We applied these various assays to the cell-based lead optimization of the imidazopyrazines, exemplified by 3 (KAI407), and show that optimized compounds within the series with improved pharmacokinetic properties achieve causal prophylactic activity in vivo and may have the potential to target the dormant stages of P. vivax malaria.
COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
-
, (2014/06/11)
The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease, such as malaria, caused by a Plasmodium parasite.
